吉西他滨治疗复发、难治性非霍奇金淋巴瘤疗效的研究进展
|
摘要
我国淋巴瘤的主要分型为非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL),其经典的化疗方案为CHOP方案,50%-60%的患者获得完全缓解,但其中一半病例出现复发或者发展为难治型病例。对于这部分患者目前迫切需要寻找一种高效、低毒的治疗方案。本文就几个主要包含吉西他滨的方案在中国人群中治疗复发、难治性非霍奇金淋巴瘤的疗效做一综述。
The main type of lymphoma in China is non- Hodgkin's lymphoma( non- Hodgkin' s lymphoma,NHL).The classic chemotherapy scheme for the CHOP,50%- 60% of the patients received complete remission,but half of cases will be recurrent or develop difficult cases. In this part of patients there is an urgent need to find a high efficient and low toxicity treatment. In this paper,several main contain gemcitabine scheme in the Chinese population with of recurrent and refractory non- hodgkin's lymphoma were reviewed.
The main type of lymphoma in China is non- Hodgkin's lymphoma( non- Hodgkin' s lymphoma,NHL).The classic chemotherapy scheme for the CHOP,50%- 60% of the patients received complete remission,but half of cases will be recurrent or develop difficult cases. In this part of patients there is an urgent need to find a high efficient and low toxicity treatment. In this paper,several main contain gemcitabine scheme in the Chinese population with of recurrent and refractory non- hodgkin's lymphoma were reviewed.
引文
[1]马树东,盛信秀,罗荣城,等.盐酸吉西他滨治疗复发性或难治性非霍奇金淋巴瘤[J].中华肿瘤杂志,2002,24:619-621.
[2]朱蔚友,束永前.吉西他滨治疗晚期非小细胞肺癌的现状及进展[J].临床肿瘤学杂志,2004,9(1):94-99.
[3]Bergman AM,Pinedo HM,Talianidis I,et al.Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines[J].Br J Cancer,2003,88:1963-1970.
[4]Fossa A,Santoro A,Hiddemann W,et al.Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive nonHodgkin's lymphoma[J].J Clin Oncol,1999,17:3786-3792.
[5]王淑梅.吉西他滨单药治疗晚期非霍奇金淋巴瘤20例分析[J].中国误诊学杂志,2008,8(25):6250-6251.
[6]卞伟钢.吉西他滨联合顺铂治疗晚期肺癌30例临床观察[J].实用临床医药杂志,2006,3:56.
[7]赵文英,陈冬云,陈景华.香菇多糖联合吉西他滨+顺铂方案一线治疗晚期非小细胞肺癌近期疗效与不良反应观察[J].中国临床药理学与治疗学,2013,18(1):71-77.
[8]Peters GJ,Bergman AM,Ruiz van Haperen VW,et al.Interaction between cisplatin and gemcitabine in vitro and in vivo[J].Semin Oncol,1995,22(4suppl 11):72-79.
[9]Bergman AM,Ruiz Van Haperen VW,Veerman G,et al.Synergistic interaction between cisplatin and gemcitabine in vitro[J].Clin Cancer Res,1996,2(3):521-530.
[10]Arkenau HT,Chong G,Cunninghafl D,et al.Gemeitabine,cisplatin and methylprednisolone for the treatment of patients with peripheral T-Cell lymphoma:The Royal Marsden Hospital experience[J].Haematologica,2007,92(2):271-272.
[11]洪卫,范云,张沂平,等.吉西他滨联合顺铂治疗复发或难治性非霍奇金淋巴瘤[J].浙江临床医学,2008,10(5):584-585.
[12]NCCN非霍奇金淋巴瘤临床实践指南专家组.非霍奇金淋巴瘤临床实践指南(中国版)[J].癌症,2007,6:11.
[13]Aribi M,Mesli N,Remla N,et al.Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients:A prospective randomized trial in Algeria[J].J Cancer Res Ther,2010,6(1):41-46.
[14]肖谜,左丽,吉西他滨联合顺铂及地塞米松治疗复发或难治性非霍奇金淋巴瘤临床观察[J].中华临床医师杂志(电子版),2013,7(3):1312-1313.
[15]杨宏山,汪新菊,瞿广桥.GDP方案治疗复发性非霍奇金淋巴瘤27例[J].肿瘤研究和临床,2009,21(10):700-702.
[16]范云,黄志煜,罗吕宏,等.GDP方案治疗24例复发、耐药侵袭性非霍奇金淋巴瘤临床分析[J].中华癌症杂志,2008,27(11):1222-1225.
[17]陈少谊,罗金光,张江,等.吉西他滨联合顺铂、地塞米松治疗原发纵隔弥漫大B细胞淋巴瘤近期疗效分析[J].临床军医杂志,2011,40(6):1530-1532.
[18]缪继东.吉西他滨联合奥沙利铂治疗复发性B细胞淋巴瘤的近期疗效观察[J].实用医院临床杂志,2012,9(5):197-199.
[19]张呈,陈昌南,林云笑,等.吉西他滨联合奥沙利铂和左旋门冬酰胺酶治疗复发性或难治性非霍奇金淋巴瘤[J].现代肿瘤医学,2012,19(3):548-550.
[20]Lopez A,Gutierrez A,Palacios A,et al.GEMOX-regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma:A phaseⅡstudy[J].Eur J Haematol,2008,80(2):127-132.
[21]陆颖,黄海欣,李桂生.GEMOX方案与GDP方案治疗复发或难治性非霍奇金淋巴瘤的临床对比研究[J].中国癌症杂志,2011,21(8):621-625.
[22]倪国华,吕真,袁锁娟.吉西他滨联合顺铂加地塞米松治疗复发性或难治性非霍奇金淋巴瘤[J].临床肿瘤学杂志,2008,13(10):920-922.
[23]王小倩,张明智.吉西他滨联合奥沙利铂、甲泼尼龙治疗复发难治性非霍奇金淋巴瘤的疗效[J].山东医药,2012,52(48):58-59.
[2]朱蔚友,束永前.吉西他滨治疗晚期非小细胞肺癌的现状及进展[J].临床肿瘤学杂志,2004,9(1):94-99.
[3]Bergman AM,Pinedo HM,Talianidis I,et al.Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines[J].Br J Cancer,2003,88:1963-1970.
[4]Fossa A,Santoro A,Hiddemann W,et al.Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive nonHodgkin's lymphoma[J].J Clin Oncol,1999,17:3786-3792.
[5]王淑梅.吉西他滨单药治疗晚期非霍奇金淋巴瘤20例分析[J].中国误诊学杂志,2008,8(25):6250-6251.
[6]卞伟钢.吉西他滨联合顺铂治疗晚期肺癌30例临床观察[J].实用临床医药杂志,2006,3:56.
[7]赵文英,陈冬云,陈景华.香菇多糖联合吉西他滨+顺铂方案一线治疗晚期非小细胞肺癌近期疗效与不良反应观察[J].中国临床药理学与治疗学,2013,18(1):71-77.
[8]Peters GJ,Bergman AM,Ruiz van Haperen VW,et al.Interaction between cisplatin and gemcitabine in vitro and in vivo[J].Semin Oncol,1995,22(4suppl 11):72-79.
[9]Bergman AM,Ruiz Van Haperen VW,Veerman G,et al.Synergistic interaction between cisplatin and gemcitabine in vitro[J].Clin Cancer Res,1996,2(3):521-530.
[10]Arkenau HT,Chong G,Cunninghafl D,et al.Gemeitabine,cisplatin and methylprednisolone for the treatment of patients with peripheral T-Cell lymphoma:The Royal Marsden Hospital experience[J].Haematologica,2007,92(2):271-272.
[11]洪卫,范云,张沂平,等.吉西他滨联合顺铂治疗复发或难治性非霍奇金淋巴瘤[J].浙江临床医学,2008,10(5):584-585.
[12]NCCN非霍奇金淋巴瘤临床实践指南专家组.非霍奇金淋巴瘤临床实践指南(中国版)[J].癌症,2007,6:11.
[13]Aribi M,Mesli N,Remla N,et al.Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients:A prospective randomized trial in Algeria[J].J Cancer Res Ther,2010,6(1):41-46.
[14]肖谜,左丽,吉西他滨联合顺铂及地塞米松治疗复发或难治性非霍奇金淋巴瘤临床观察[J].中华临床医师杂志(电子版),2013,7(3):1312-1313.
[15]杨宏山,汪新菊,瞿广桥.GDP方案治疗复发性非霍奇金淋巴瘤27例[J].肿瘤研究和临床,2009,21(10):700-702.
[16]范云,黄志煜,罗吕宏,等.GDP方案治疗24例复发、耐药侵袭性非霍奇金淋巴瘤临床分析[J].中华癌症杂志,2008,27(11):1222-1225.
[17]陈少谊,罗金光,张江,等.吉西他滨联合顺铂、地塞米松治疗原发纵隔弥漫大B细胞淋巴瘤近期疗效分析[J].临床军医杂志,2011,40(6):1530-1532.
[18]缪继东.吉西他滨联合奥沙利铂治疗复发性B细胞淋巴瘤的近期疗效观察[J].实用医院临床杂志,2012,9(5):197-199.
[19]张呈,陈昌南,林云笑,等.吉西他滨联合奥沙利铂和左旋门冬酰胺酶治疗复发性或难治性非霍奇金淋巴瘤[J].现代肿瘤医学,2012,19(3):548-550.
[20]Lopez A,Gutierrez A,Palacios A,et al.GEMOX-regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma:A phaseⅡstudy[J].Eur J Haematol,2008,80(2):127-132.
[21]陆颖,黄海欣,李桂生.GEMOX方案与GDP方案治疗复发或难治性非霍奇金淋巴瘤的临床对比研究[J].中国癌症杂志,2011,21(8):621-625.
[22]倪国华,吕真,袁锁娟.吉西他滨联合顺铂加地塞米松治疗复发性或难治性非霍奇金淋巴瘤[J].临床肿瘤学杂志,2008,13(10):920-922.
[23]王小倩,张明智.吉西他滨联合奥沙利铂、甲泼尼龙治疗复发难治性非霍奇金淋巴瘤的疗效[J].山东医药,2012,52(48):58-59.